Memantine Treatment Study of Pathological Gambling

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Pathological Gambling
Interventions
DRUG

Memantine Hydrochloride

10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.

Trial Locations (2)

55454

University of Minnesota Medical Center, Fairview, Minneapolis

06519

Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Minnesota

OTHER

collaborator

Forest Laboratories

INDUSTRY

lead

Yale University

OTHER